Navigation Links
Delta-Aminolevulinic Acid, Urine

ProductsDelta-Aminolevulinic Acid, Urine
Company ARUP Laboratories
Item Delta-Aminolevulinic Acid, Urine
Features 
Description ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' clients include more than half of the nation's university teaching hospitals and children's hospitals, major commercial laboratories, military and government facilities, and major clinics.
Info ARUP Laboratories
Customer Service: (800) 522-2787
Web site: http://www.aruplab.com

Related medicine products :

1. Acid, Urine
2. Aminocaproic Acid, Serum or Plasma
3. Aminocaproic Acid, Urine
4. Carbolic Acid, Urine
5. Citric Acid, Serum
6. Citric Acid, Urine
7. 2,4-Dichlorophenoxyacetic Acid, Serum or Plasma
8. 2,4-Dichlorophenoxyacetic Acid, Urine
9. Fatty Acid, Stool
10. Formic Acid, Urine
11. Formic Acid, Serum or Plasma
With the touch of a button, the Marco Encore Automatic Chair quickly reclines from an upright position to a fully horizontal, flat-table mode-or anywhere in between.
Bulb Direct has been selling replacement bulbs on the Internet since 1996, and we are extremely proud of our 100% satisfaction guarantee. Check out our catalog of replacement bulbs and see our discou
Bulb Direct has been selling replacement bulbs on the Internet since 1996, and we are extremely proud of our 100% satisfaction guarantee. Check out our catalog of replacement bulbs and see our discou
Bulb Direct has been selling replacement bulbs on the Internet since 1996, and we are extremely proud of our 100% satisfaction guarantee. Check out our catalog of replacement bulbs and see our discou
Medicine Products:
(Date:12/3/2008)...yperdrug are offering free shipping to the end of ...mber 2, 2009 -- For the remainder of the year stan...tment Frontline , to UK mainland addresses, exclud...tomers entering the special voucher code SHIP4FREE...irector Ben Watson says "Hyperdrug intends to...
(Date:12/3/2008)...wswire/ -- Two cities in Tennessee have adopted,N... Campaign" (MWC) it was,learned this week. An ar...y,reported that the cities of Athens and Englewoo...ed of the New Jersey program through their health ...yurl.com/69kabf ) , The Mayors Wellness Ca...
(Date:12/3/2008)...UCLA have proven definitively that blood stem cell...pment by endothelial cells, the cells that line th...c location in the embryo where blood stem cells or...om which they spring was less understood. The UCLA...he journal Cell Stem Cell , puts to rest a long-s...
(Date:12/3/2008)...y pressure (CPAP) treatment seems to improve cogni...ase who also suffer from obstructive sleep apnea, ...trial conducted at the University of California, S...h.D., professor of psychiatry at the UC San Diego ...ent experts in the field of sleep disorders and sl...
Breaking Medicine News(10 mins):Health News:Beating the Credit Crunch with Hyperdrug.co.uk 2Health News:New Jersey's 'Mayors Wellness Campaign' Goes National! 2Health News:UCLA scientists prove endothelial cells give rise to blood stem cells 2Health News:UCLA scientists prove endothelial cells give rise to blood stem cells 3Health News:Treating sleep apnea in Alzheimer's patients helps cognition 2Health News:Treating sleep apnea in Alzheimer's patients helps cognition 3
... revealed that there is a “crisis” over lack of do...with some of the clinics being totally out of stoc...re facing a major problem. In 1990s, the highest ...e number had been decreasing. To make it worse, la...
...diologists in US is asking for an extensive study ...ing fatal blood clots on the use of stents. // St...ked heart arteries, these drug eluting stents are ...restenosis as a complication of coronary angioplas...
...ging (MRI) could be a safe way to monitor the fate...dy in the September issue of the journal Diabetes....dical Imaging at Massachusetts General Hospital (M... islets in mice using the guidelines laid down for...
...aboratories Ltd Tuesday launched its branded inhal...a//. A unique combination of long acting Beta2-ag...costeroid Fluticasone, the inhalation capsule Aves..., Avessa 250 mcg, Avessa 500 mcg, depending on the...
Other Medicine News:Health News:Shortage of donors at sperm bank clinics 2Health News:MRI Can Monitor Transplanted Islets 2
(Date:12/3/2008)...IEGO, Dec. 3 Vical Incor...usive, binding letter of intent with EIP,Eczaciba...ng of the company,s,Allovectin-7(R) immunotherape...Republic of Northern Cyprus. EIP has agreed to obt...rritory and to pay Vical upfront and milestone pay...
(Date:12/2/2008)...GO, Dec. 3 Breast-speci...ction of cancers not found on mammograms or by,cl...at the annual meeting of,the Radiological Society...ify the most difficult to detect breast cancer-inv... F. Brem, M.D., professor of,radiology and direct...
(Date:12/2/2008)...A, Kan., Dec. 2 IBT Laboratories, ...earch laboratory specializing in immunology and al...tests to evaluate the response of patients whose ... immunodeficiency disorder, chemotherapy drugs, or...to prevent rejection of a transplant. The company ...
(Date:12/2/2008)...E, Ill., Dec. 2 Horizon Therapeuti...any, today announced that two pivotal,Phase 3 tri...ndidate, HZT-501,met all primary endpoints. HZT-...product containing ibuprofen and famotidine, demon...the incidence of non-steroidal,anti-inflammatory ...
Breaking Medicine Technology:Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 2Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 3Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 4Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 5New Breast Imaging Technology Targets Hard-to-Detect Cancers 2New Breast Imaging Technology Targets Hard-to-Detect Cancers 3IBT Laboratories Expands its Menu of Tests for Immune Deficiency 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4Plastic Surgeon Joins Established Practice 13056 1Plastic Surgeon Joins Established Practice 13056 24th annual Templeton Cambridge fellowships awarded to 10 noted journalists 13054 14th annual Templeton Cambridge fellowships awarded to 10 noted journalists 13054 24th annual Templeton Cambridge fellowships awarded to 10 noted journalists 13054 34th annual Templeton Cambridge fellowships awarded to 10 noted journalists 13054 4BioInformatics LLC Studies Trade Show Exhibition Strategies in the Life Science Market 3600 1BioInformatics LLC Studies Trade Show Exhibition Strategies in the Life Science Market 3600 2BioInformatics LLC Studies Trade Show Exhibition Strategies in the Life Science Market 3600 3Emeril Lagasse and Planet Green Partner with Whole Foods Market 28R 29 on Innovative New Series 13051 1Emeril Lagasse and Planet Green Partner with Whole Foods Market 28R 29 on Innovative New Series 13051 2Emeril Lagasse and Planet Green Partner with Whole Foods Market 28R 29 on Innovative New Series 13051 3
... in Blood Glucose,Control and Progressive Weight L...l/ -- Amylin,Pharmaceuticals, Inc. and Eli Lilly a...at showed BYETTA(R) (exenatide) injection,sustaine...ve weight,loss through three and a half years of t...improvements in cardiovascular risk,factors in peo...
... 25, 2007--Gilead,Sciences, Inc. (Nasdaq:GILD) tod...trial evaluating the company,s once-daily,anti-HIV...tenofovir,DF) 300 mg as a potential treatment for ... primary efficacy endpoint. The data show,that Vir...tiviral,drug Hepsera(R) (adefovir dipivoxil) among...
Other Medicine Technology:Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 2Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 3Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 4Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 5Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 6Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 2Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 3Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 4Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 5Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 6